How it works, simply
It activates GLP-1 receptors involved in appetite and blood-sugar regulation.
What the evidence tells us
Schedules being tested in a trial are not instructions for a retail research vial.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
This guide does not establish a safe dose, interaction profile or long-term safety for self-use. Effects reported for one route or formulation may not apply to another.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Activates GLP-1 receptors; weekly and monthly regimens are being studied.
Sponsor or developer: Pfizer
Studied or labeled topics: Obesity
2026-02-03: Sponsor reported Phase 2b findings and initiation of Phase 3 VESPER-4. Planned trials should not be read as completed trials.
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- Pfizer: VESPER-3 results and VESPER-4 initiation ↗ · Sponsor · 2026-02-03
Readability updated October 10, 2026. Evidence review: September 23, 2026 (listed facts only). A wording update is not a new clinical review.